Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Spyre Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Spyre Therapeutics, Inc.

SYRE

Spyre Therapeutics, Inc.

About Spyre Therapeutics, Inc.

Spyre Therapeutics, Inc. is a clinical-stage biotech focused on developing next-generation antibody therapies for inflammatory bowel disease (IBD) and immune-mediated diseases. Its pipeline includes engineered monoclonal antibodies targeting α4β7, TL1A, and IL-23, designed for improved efficacy, safety, and dosing convenience. The company emphasizes combination therapies and expansion into indications like rheumatoid arthritis, leveraging innovative antibody engineering and strategic partnerships.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Spyre Therapeutics, Inc.

1
1
Spyre Therapeutics, Inc. Spyre Therapeutics Reports $69M Net Loss in Q1 2026, Increases R&D Spending

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Spyre Therapeutics, Inc. Spyre Therapeutics Reports $155.2M Net Loss and Operational Updates in Annual Filing

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
Spyre Therapeutics, Inc. Spyre Therapeutics Reports $11.2 Million Net Loss in Q3 2025, Highlights Clinical Advancements

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Spyre Therapeutics, Inc. Spyre Therapeutics Reports $36.7 Million Net Loss, Decreases Total Assets to $538.8 Million

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Spyre Therapeutics, Inc. Spyre Therapeutics Reports $44.8 Million Net Loss in Q1 2025, Increases R&D Spending

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Spyre Therapeutics, Inc. Spyre Therapeutics Reports Financial Results for Q3 2024, Net Loss of $69M

Via official filing (AI summary) | over 1 year ago | 0 comments